Cryolife (NYSE:CRY) updated its FY 2019 earnings guidance on Tuesday. The company provided earnings per share guidance of $0.28-0.32 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.30. The company issued revenue guidance of $280-284 million, compared to the consensus revenue estimate of $282.2 million.

Several brokerages have commented on CRY. ValuEngine upgraded shares of Vermillion from a hold rating to a buy rating in a research report on Wednesday, May 15th. Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a report on Tuesday, April 23rd. TheStreet downgraded shares of Wayside Technology Group from a b- rating to a c rating in a report on Wednesday, May 22nd. Needham & Company LLC reiterated a buy rating and set a $5.00 price target on shares of SCYNEXIS in a report on Sunday, May 12th. Finally, Canaccord Genuity upped their price target on shares of TELUS from C$51.00 to C$52.00 in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $31.91.

Shares of Cryolife stock traded up $0.27 during trading on Tuesday, hitting $30.49. The company’s stock had a trading volume of 114,738 shares, compared to its average volume of 188,790. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.69 and a current ratio of 4.90. Cryolife has a 52 week low of $23.99 and a 52 week high of $36.05. The stock has a market capitalization of $1.13 billion, a PE ratio of 117.27 and a beta of 0.59. The firm’s 50-day moving average is $30.01.

Cryolife (NYSE:CRY) last issued its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting the consensus estimate of $0.04. The company had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $66.37 million. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. Cryolife’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 earnings per share. Analysts predict that Cryolife will post 0.31 EPS for the current fiscal year.

In other Cryolife news, VP Jean F. Holloway sold 8,654 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $32.00, for a total transaction of $276,928.00. Following the sale, the vice president now owns 67,020 shares of the company’s stock, valued at $2,144,640. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP David Ashley Lee sold 25,255 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $31.36, for a total transaction of $791,996.80. Following the sale, the vice president now directly owns 300,910 shares in the company, valued at approximately $9,436,537.60. The disclosure for this sale can be found here. Insiders have sold 99,609 shares of company stock worth $3,112,863 in the last ninety days. Insiders own 4.40% of the company’s stock.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: Do back-end load funds outperform no-load funds?

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with's FREE daily email newsletter.